Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than with chemotherapy alone.

Saved in:

Bibliographic Details
Published in:	The New England journal of medicine Vol. 388; no. 23; pp. 2159 - 2170
Main Authors:	Eskander, Ramez N., Sill, Michael W., Beffa, Lindsey, Moore, Richard G., Hope, Joanie M., Musa, Fernanda B., Mannel, Robert, Shahin, Mark S., Cantuaria, Guilherme H., Girda, Eugenia, Mathews, Cara, Kavecansky, Juraj, Leath, Charles A., Gien, Lilian T., Hinchcliff, Emily M., Lele, Shashikant B., Landrum, Lisa M., Backes, Floor, O’Cearbhaill, Roisin E., Al Baghdadi, Tareq, Hill, Emily K., Thaker, Premal H., John, Veena S., Welch, Stephen, Fader, Amanda N., Powell, Matthew A., Aghajanian, Carol
Format:	Journal Article
Language:	English
Published:	United States Massachusetts Medical Society 08.06.2023
Subjects:	Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Cancer therapies Carboplatin Carboplatin - administration & dosage Carboplatin - adverse effects Chemotherapy Cytotoxicity DNA Mismatch Repair Double-Blind Method Endometrial cancer Endometrial Neoplasms - drug therapy Endometrial Neoplasms - genetics Endometrial Neoplasms - mortality Endometrial Neoplasms - pathology Endometrium Female Gynecologic Oncology Gynecology Hematology Humans Hypotheses Immunotherapy Laboratories Mismatch repair Monoclonal antibodies Obstetrics Oncology Paclitaxel Paclitaxel - administration & dosage Paclitaxel - adverse effects Pembrolizumab Placebos Statistical analysis Survival Targeted cancer therapy Treatments in Oncology Tumors Japan
ISSN:	0028-4793, 1533-4406, 1533-4406
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!